alessia ligresti – curriculum vitae - cnr · alessia ligresti – curriculum vitae january -...

Alessia Ligresti – Curriculum Vitae

Date and Place of birth: October 11, 1975; Minturno (LT), Italy

Nationality: Italian

Email: [email protected]

MAIN RESEARCH INTERESTS

– Studies on the role of cannabinoids and endocannabinoid system on cancer

disease

– Studies on the role of neuroendocrine trans-differentiation in prostate cancer

development and drug resistance

– Studies on structure activity relationship (SAR) for selective inhibitors of

Endocannabinoid-related targets (i.e. EMT, CBR, TRP, metabolic enzymes)

– Design, synthesis and characterization of biodegradable nano-particles for

targeted and controlled release of bioactive molecules in animal and cellular

models of highly disabling diseases.

– Use of ligand modified nanoparticles for the study of cellular membrane

trafficking of lipid bioregulators and bioactive amides of fatty acids

– Biosynthesis, bioactivity and inactivation of prostamides in the CNS.

– Studies on the role of Endogenous Cannabinoids and Brain/Immune Function

– Role of Endocannabinoid System in Obesity and Metabolic Syndrome

NUMBER OF PUBLICATIONS CORRELATED TO MAIN RESEARCH

INTERESTS: 29 articles, chapters in book and reviews in international journals,

personal H-index: 34, Total number of citations: 4845 [Source: Scholar, February

2017]).

ACADEMIC AND RESEARCH CARRIER

2014 Habilitation as Associate Professor in Biochemistry and Clinical Biochemistry

from MIUR (Ministry of Education, University and Research)

2005 PhD Degree in Pharmaceutical Science, University of Naples “Federico II”,

Facoltà di Farmacia, discussing the experimental thesis:

“Cannabinoids and Endocannabinoid on Cancer disease”

2001 MS Degree in Chemical and Pharmaceutical Technology, University of Naples

“Federico II”, Facoltà di Farmacia discussing the experimental

thesis: “The inhibitor effect of propolis and caffeic acid phenethyl

ester on ciclooxygenase activity in J774 macrophages”

POSITION HELDS

From March 2012 to March 2016 Scientific Consultant for Allergan Inc.

(Irvine, California)

Since January 2010 Research Associate Professor at Institute of Biomolecular

Chemistry, CNR.

Since January 2008 Research Investigator at Institute of Biomolecular

Chemistry, CNR.

Since September 2006 Winner of a National Public Contest (code NA19/1) as

Research Investigator at CNR.

2005-2006 Semestral grant on Endogenous Cannabinoids and Brain/Immune

Function, Endocannabinoid Research Group, Institute of Biomolecular

Chemistry, Pozzuoli (Napoli), Italy. (Research Project Supervisor).


January - October 2005 Department of Biological Science, Allergan Inc.,

Irvine, California USA (Visiting Researcher).

Since January 2004 Preclinical Research Collaborator for GW Pharmaceutical

(project codes GWCRI1173 and GWCRI1649).

June 2005 - June 2007 Student Representative for International Cannabinoid

Research Society.

2004-2005 Annual grant based on Biosynthesis, bioactivity and inactivation

of prostamides in the CNS, Endocannabinoid Research Group, Institute of

Biomolecular Chemistry, Pozzuoli (Napoli), Italy. (Research Project

Supervisor).

2003-2004 Annual grant based on Research of the potentiality activity of

vegetable compounds on vanilloid and cannabinoid receptors, Endocannabinoid

Research Group, Institute of Biomolecular Chemistry, Pozzuoli (Napoli), Italy.

(Research Project Supervisor).

2002-2003 Annual grant based on Biosynthesis, bioactivity and inactivation of

prostamides in the CNS, Endocannabinoid Research Group, Institute of

Biomolecular Chemistry, Pozzuoli (Napoli), Italy. (Research Project

Coordinator).

2001-2002 Annual grant based on Pharmacological activity of fatty acids

bioactive amides, Endocannabinoid Research Group, Institute of Biomolecular

Chemistry, Pozzuoli (Napoli), Italy. (Research Project Coordinator).

INTERNATIONAL AND NATIONAL AWARDS FOR SCIENTIFIC

ACHIEVEMENTS

Elected by the Steering Committee as Promising Leader for “Future Directions

in Gastroenterology and Appetite Control” at the Annual Workshop of Astra

Zeneca, 29th April-1st May-2009 Gothenburg, Sweden.

Student representative Award for outstanding work in the Cannabinoid Field for

the International Cannabinoid Research Society.

Award for an outstanding scientific presentation at the 2004 Symposium on the

Cannabinoid, June 2004- Paestum, Italy.

Gordon Research Conference travel award, Biddeford, Maine.

International Cannabinoid Research Society (ICRS) travel award; 2008,

Aviemore, Scotland.

International Cannabinoid Research Society (ICRS) travel award; 2007, Sain-

Sauveir, Quebec.

International Cannabinoid Research Society (ICRS) travel award; 2006, Tihany,

Hungary.

PATENTS

US Patent Application 20130059018 - PHYTOCANNABINOIDS IN THE

TREATMENT OF CANCER [Application 20130059018 Filed on March 11,

2011. Published on March 7, 2013].

ITALIAN Patent Application NA2010A000030 - Sostituzione bioisosterica del

gruppo ammidico di 4-chinolon-3-carbossamidi 6-sostituite: ligandi CB2 potenti

e selettivi provvisti di miglior profilo chimico-fisico. [Filed on June 23, 2010].


MANAGEMENT OF INTERNATIONAL AND NATIONAL RESEARCH

PROJECTS

1. Title of the research project: INnovative Life sCIence Phd Programme in South

ITaly — INCIPIT. Project Start/End dates: January 2016/December 2016.

Granting Agency: H2020-MSCA-COFUND. Gross Amount: 2.000.000€. Role:

PhD Supervisor-Research Project Coordinator. 2. Title of the research project: New therapeutic strategies based on

endocannabinoids, endovanilloids and bioactive amines of fatty acids. Project

Start/End dates: January 2016/December 2016. Granting Agency: CNR internal

grant reassignment. Gross Amount: 195.000€. Role: Principal Investigator.

3. Title of the research project: Behavioral, proteomic and lipidomic analyses in

adult male and female rats exposed to cannabinoids during adolescence: an

integrative approach to identify markers of vulnerability for psychiatric disorders

and drug abuse. Project Start/End dates: August 2009/September 2012. Granting

Agency: Compagnia di San Paolo (Programma Neuroscienze). Gross Amount:

300.000€. Role: Principal Investigator.

4. Title of the research project: Chemical and Pharmacogical Characterization of

Cannabis Extracts. Project Start/End dates: February 2003/ongoing. Granting

Agency: GW Pharmaceuticals. Gross Amount: 312.000€/per year. Role: Research

Project Coordinator.

5. Title of the research project: Elevation of FAA levels and activation of

CB/TRPV/prostamide receptors as a New Therapeutic Strategy. Project Start/End

dates: January 2005/ongoing. Granting Agency: Allergan Inc. Gross Amount:

190.000€/per year. Role: Research Project Coordinator.

6. Title of the research project: Role of endocannabinoid system in the peripheral

control of energy balance and fat mass: animal and clinical studies and possible

mechanism(s) of action. Project Start/End dates: April 2005/ April 2009.

Granting Agency: Sanofi-Aventis. Gross Amount: 276.000€. Role: Research

Project Coordinator.

INVITED SPEAKER AT INTERNATIONAL SCIENTIFIC MEETINGS

1. Second Endocannabinoid Pharmacology Meeting, 29th-30th October. Targeting

pain and inflammation by combining FAAH inhibition and multiple prostanoid

receptor antagonism: one stone to kill two birds.

2. Annual Workshop of Astra Zeneca “Future Directions in Gastroenterology and

Appetite Control” 29thApril-1stMay Gothenburg, Sweden. Peripheral

endocannabinoid dysregulation in obesity.

ORAL COMMUNICATIONS AT INTERNATIONAL SCIENTIFIC MEETINGS

1. 26th Symposium on the cannabinoids of the ICRS (International Cannabinoid

Research Society). Bukovina, Poland 26 June-01 July 2016. Role of cannabinoids in

a multistage murine model of prostate carcinoma to investigate potential clinical

applications. Alessia Ligresti, Roberto Ronca, Viviana Marolda, Daniela Coltrini

and Vincenzo Di Marzo


2. 14th International Conference on Bioactive Lipids in Cancer, Inflammation and

related Disorders. Budapest, July 12-15, 2015. Targeting pain and inflammation by

combining two therapeutic modalities in a single molecule: inhibition of FAAH and

antagonism of multiple prostanoid receptors. Ligresti A, Woodward DF, Wang JW,

Silvestri C, Martos J, Maione S, Marino G and Di Marzo V.

3. First Joint Spanish-Italian meeting on Cannabinoid Research. Madrid, November

29th- December 1st 2012. Role of cannabinoids in prostate cancer: Focus on CBD

pro-apoptotic mechanisms and potential clinical applications. Alessia Ligresti,

Roberta Verde, Luciano De Petrocellis, Luigia Cristino, Aniello Schiano Moriello,

Pierangelo Orlando and Vincenzo Di Marzo.


Research Society). July 5-10, 2011. St. Charles, Illinois. Mechanisms of the anti-

cancer effects of cannabidiol and other non-psychotropic cannabinoids on human

prostate carcinoma. Alessia Ligresti, Luciano De Petrocellis, Aniello Schiano

Moriello, Roberta Verde, Piero Orlando and Vincenzo Di Marzo.

5. GW-Otsuka Annual Scientific Review, March 15-16, 2011. London. Why is

prostate cancer a legitimate target for cannabinoids? Alessia Ligresti, Luciano De

Petrocellis, Aniello Schiano Moriello, Roberta Verde, Piero Orlando and Vincenzo

Di Marzo.


Research Society). July 7-11, 2009. St. Charles, Illinois. Nanoparticle-mediated

cellular uptake-controlled release as a tool to study anandamide membrane

transport. Alessia Ligresti, Dolores Hernan Perez de la Ossa, Jesús Molpeceres,

Rosario Aberturas, Mª Esther Gil, Aniello Schiano Moriello, Ana-Isabel Torres,

Luciano De Petrocellis and Vincenzo Di Marzo.


Research Society). Aviemore 25-30 June 2008. Stereo- and enantio-specific activity

of fatty acid cyclopropanolamides at cannabinoid and vanilloid receptors. Alessia

Ligresti, Alberto Minassi, Luciano De Petrocellis, Orazio Taglialatela-Scafati,

Marco Allarà, Giovanni Appendino and Vincenzo Di Marzo.


Research Society). Saint-Sauveur, Quebec (Canada). 26-30, June 2007.

Overactivation of the endocannabinoid system in human endometrial carcinoma.

Ligresti A, De Filippis D, Orlando P, Guida M, Nigam S, Petrosino S, Di Marzo V

and Iuvone T.


Research Society). Tihany, Hungary Anti-cancer effects of cannabidiol in human

breast carcinoma: cellular and molecular mechanisms of action and inhibition of

metastatic spreading. 24-26 June 2006. Ligresti A, Schiano Moriello A, Matias I,

Starowicz K, Pisanti S, De Petrocellis L, Portella G, Bifulco M and Di MarzoV.


Research Society). Paestum, Salerno (Italy) 23-27, July 2004. Effect of plant

cannabinoids on cancer cell proliferation. Ligresti A., De Petrocellis L ., Schiano

Moriello A., Portella G., Bifulco M. and Di Marzo V.

POSTER COMMUNICATIONS AT INTERNATIONAL SCIENTIFIC

MEETINGS


1. Gordon Research Conference on Cannabinoid Function in the CNS. August 2-7,

2009. Biddeford, Maine. A novel approach to evaluate anandamide membrane

transport into intact cells by using nanoparticle-mediated cellular uptake and

controlled release. Alessia Ligresti, Dolores Hernan Perez de la Ossa, Jesús

Molpeceres, Rosario Aberturas, Mª Esther Gil, Ana-Isabel Torres, Luigia Cristino,

Luciano De Petrocellis and Vincenzo Di Marzo.

2. “Frontiers in CNS and oncology Medicinal Chemistry” Siena (Italia), 7-9, October

2007. Potential tumor-inhibitory action by endocannabinoids in uterine neoplasias.

Alessia Ligresti, Daniele De Filippis, Maurizio Guida, Santosh Nigam, Stefania

Petrosino, Teresa Iuvone and Vincenzo Di Marzo.

3. 4th International Conference on Phospholipase A2 and Lipid Mediators. May 25-28,

2009. Tokyo, Japan. Endocannabinoids are endogenously over produced in highly

malignant ovarian carcinoma: possible involvement of COX-2 with their tonic

control of cancer spreading and potential pharmacological relevancies. Alessia

Ligresti, Rupal Deva, Stefania Petrosino, Santosh Nigam and Vincenzo Di Marzo.

4. Second European Workshop on Cannabinoid Research, Busto Arsizio (Va) 29-30,

April 2005. Effect of plant cannabinoids on cancer. Ligresti A, Schiano Moriello A,

Matias I, De Petrocellis L, Pisanti S, Bifulco M, Portella G and Di Marzo V.

5. First Italian Workshop on Endocannabinoids. Fisciano, Salerno 5 December, 2003.

Studi su inibitori del trasporto facilitato dell’anandamide inattivi sulla “fatty acid

amidohydrolase”. Ligresti A., Ortar G., Morera E. and Di Marzo V.


Research Society). Cornwall, Ontario (Canada) 24-28, 2003. Novel selective and

metabolically stable inhibitors of Anandamide cellular uptake. Ligresti A., Ortar

G., de Lago E., De Petrocellis L., Morera E., Fernandez-Ruiz J. and Di Marzo V.

7. First European Workshop on Cannabinoid Research. Madrid 4-5 April, 2003.

Endocannabinoid control of colorectal cancer growth. Ligresti A., Bisogno T.,

Matias I., De Petrocellis L., Laezza C., Cascio M.G., Cosenza V., D’Argenio G.,

Scaglione G., Bifulco M., Sorrentini M., Di Marzo V.

8. National workshop of pool of sciences and technology for life. Naples, June 14-15,

2001. The inhibitor effect of propolis and caffeic acid phenethyl ester on

cicloxygenase activity in rat lung. Ligresti A., Rossi A., Longo R., Russo A.,

Borrelli F., Sautebin L.

PARTECIPATION IN TEACHING PROGRAMS/SCIENTIFIC DIVULGATION:

Title of project: Alternanza Scuola Lavoro

Course: Introduction to Pharmacology and Drug-discovery

Role: Teacher and lab training coordinator

Year: 2016

Title of project: Molecole Senza Frontiere (MoSeF)

Mission and Main Activities: MoSeF is a network of researchers that aim to create an

effective strategy for interdisciplinary dissemination based on chemistry including its

interrelationship with other disciplines and its role in everyday life. MoSeF acts by

participating in outreach events geared to the general public, to schools and to

professional users.

Role: Active member

Year: from 2015


Title of project: L’Istituto di Chimica Biomolecolare va a scuola e…le scuole vanno

all’Istituto di Chimica Biomolecolare

Course: Introduction to Biochemistry and Pharmacology

Role: Teacher and lab training coordinator

Year: 2012

PARTECIPATION IN PhD PROGRAM / TUTORING

1. PhD candidate: Ali Mokhtar. Thesis title: Role of neuroendocrine

transdifferentiation in prostate cancer development and drug resistance

Departement: Biomolecular Science. University: University of Campania. Role:

Mentoring Coordinator.

2. Post-doc candidate: Enrico D’Aniello. Project title: New therapeutic strategies

based on endocannabinoids, endovanilloids and bioactive amines of fatty acids.

Role: Scientific supervisor.

3. PhD candidate: Imen Ben Hadj Yahia. Thesis title: Isolation, characterization and

evaluation of anti tumoral properties of new metabolites from Mentha rotundifolia

and Mentha aquatica. Departement: Bioengenering. University: National Institute

of Applied Science and Technology of Tunis. Role: Mentoring Coordinator.

4. PhD candidate: Dolores Hernán Pérez de la Ossa. Thesis title: Development and in

vitro/in vivo evaluation of biodegradable microspheres for cannabinoid

vehiculization. Department: Pharmacy & Pharmaceutical Technology, School of

Pharmacy. University: Complutense University, 28040 Madrid, Spain. Role:

External Committee Member.

5. PhD candidate: Fabiana Piscitelli. Thesis title: Behavioral, proteomic and

lipidomic analyses in adult male and female rats exposed to cannabinoids during

adolescence: an integrative approach to identify markers of vulnerability for

psychiatric disorders and drug abuse. Department: Structural and Functional

Biology, Lab. of Neuropharmacology. University: University of Insubria, 21054

Busto Arsizio (VA). Role: Mentoring Coordinator.

6. Undergraduate Student: Fabrizia De Maio. Thesis title: Towards the use of non-

psychoactive cannabinoids for prostate cancer: in vitro and in vivo analyses.

Department: Science and Technology. University: University of Naples

“Parthenope”. Role: Mentoring Coordinator.

7. Undergraduate Student: Alessandro Rabbito. Thesis title: Pharmacological

characterization of novel dual-target cannabinoid receptor modulators.

Department: Molecular Medicine and Medical Biotechnology. University:

University of Naples “Federico II”. Role: Mentoring Coordinator.

8. Graduate Student: Vittoria Palmieri. Traineeship in Biotechnology on health

applications. Role: Tutoring.

9. Graduate Student: Nunzia Ciriello. Traineeship in Biotechnology on health


10. Graduate Student: Alessandra Gentile. Traineeship in Biotechnology on health


11. Undergraduate Student: Viviana Marolda. Thesis title: Role of Endocannabinoid

System in Tumor disease. Department: Molecular Medicine and Medical

Biotechnology. University: University of Naples “Federico II”. Role: Mentoring

Coordinator.


REVIEWING PROJECTS AND PUBLICATIONS:

Grant reviewer for the PRIN project, Ministry for Instruction, University and

Research (MIUR), Italy

Reviewer for the Award “Premio Nazionale Editoria Universitaria” (PNEU),

Associazione Italiana del Libro, Italy

Reviewer for the evaluation of the Italian research system (VQR), The Italian

Research and University Evaluation Agency (ANVUR), Italy

Reviewer of scientific papers sent to the journal Oncogene, British Journal of

Pharmacology, Pharmacologia, Toxicology in vitro, International Journal of

Cancer, Translational Medicine.

Frontiers in Oncology Research Topics, EDITORIAL BOARD MEMBER

MEMBER OF:

America Association for Cancer Research (AACR, since 2015)

Italian Society of Oncology (SIO, since 2015)

Italian Society of Pharmacology (SIF, since 2013)

International Cannabinoid Research Society (ICRS, since 2004)

OGRANIZING COMEETEE MEMBER: 14th Symposium on cannabinoids, Paestum (Italy) June 2004

3rd National ICB Symposium, Catania (Italy) September 2016

Judging pre- and post-doctoral presentations at meetings:

International Symposium on cannabinoids, St. Charles, Illinois USA (2009)

International Symposium on cannabinoids, Freiburg, Germany (2011)

International Symposium on cannabinoids St. Charles, Illinois USA (2012)

International Symposium on cannabinoids baveno, Italy (2014)

International Symposium on cannabinoids Bukowina, Poland (2016)

REFEREES:

Vincenzo Di Marzo:

Institute of Biomolecular Chemistry

National Research Council of Italy

[email protected]

David Woodward:

Department of Biological Sciences

Allergan Inc, Irvine CA

[email protected]

Colin Stott:

Research and Development Operations

GW Pharmaceuticals

[email protected]

mailto:Italy%[email protected]


LIST OF PUBLICATIONS

1. Silver(I) coordination polymers with 3,3 ',5,5 '-tetrasubstituted 4,4 '-bipyridine

ligands: towards new porous chiral materials. Aubert, E; Abboud, M; Doudouh, A;

Durand, P; Peluso, P; Ligresti, A; Vigolo, B; Cossu, S; Pale, P; Mamane, V.

(2017). RSC ADVANCES 7 (12): 7358-7367.

2. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids:

Pleiotropic Physiological and Pathological Roles Through Complex

Pharmacology. Ligresti A, De Petrocellis L, Di Marzo V. Physiol Rev. 2016

Oct;96(4):1593-1659. Review.

3. Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor

Type 2 Radiotracers for PET Imaging. Haider A, Müller Herde A, Slavik R,

Weber M, Mugnaini C, Ligresti A, Schibli R, Mu L, Mensah Ametamey S. Front

Neurosci. 2016 Jul 27;10:350.

4. Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as

potent and selective CB2 receptor ligands: The structural elements controlling

binding affinity, selectivity and functionality. Osman NA, Ligresti A, Klein CD,

Allarà M, Rabbito A, Di Marzo V, Abouzid KA, Abadi AH. Eur J Med Chem.

2016 Oct 21;122:619-34.

5. Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and

Butyrylcholinesterase (BuChE): Networked Targets for the Development of

Carbamates as Potential Anti-Alzheimer's Disease Agents. Montanari S, Scalvini

L, Bartolini M, Belluti F, Gobbi S, Andrisano V, Ligresti A, Di Marzo V, Rivara

S, Mor M, Bisi A, Rampa A. J Med Chem. 2016 59(13): 6387-406.

6. Design and Synthesis of New Transient Receptor Potential Vanilloid Type-1

(TRPV1) Channel Modulators: Identification, Molecular Modeling Analysis, and

Pharmacological Characterization of the N-(4-Hydroxy-3-methoxybenzyl)-4-

(thiophen-2-yl)butanamide, a Small Molecule Endowed with Agonist TRPV1

Activity and Protective Effects against Oxidative Stress. Aiello F, Badolato M,

Pessina F, Sticozzi C, Maestrini V, Aldinucci C, Luongo L, Guida F, Ligresti A,

Artese A, Allarà M, Costa G, Frosini M, Schiano Moriello A, De Petrocellis L,

Valacchi G, Alcaro S, Maione S, Di Marzo V, Corelli F, Brizzi A. ACS Chem

Neurosci. 2016 Jun 15;7(6):737-48.

7. Development and Pharmacological Characterization of Selective Blockers of 2-

Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple

Sclerosis and Pain. Brindisi M, Maramai S, Gemma S, Brogi S, Grillo A, Di

Cesare Mannelli L, Gabellieri E, Lamponi S, Saponara S, Gorelli B, Tedesco D,

Bonfiglio T, Landry C, Jung KM, Armirotti A, Luongo L, Ligresti A, Piscitelli F,

Bertucci C, Dehouck MP, Campiani G, Maione S, Ghelardini C, Pittaluga A,

Piomelli D, Di Marzo V, Butini S. J Med Chem. 2016 Mar 24;59(6):2612-32.

8. Cannabinoid pharmacology in cancer research: A new hope for cancer patients?

Javid FA, Phillips RM, Afshinjavid S, Verde R, Ligresti A. Eur J Pharmacol.

2016. Review. [Epub ahead of print].

9. Mugnaini C, Brizzi A, Ligresti A, Allarà M, Lamponi S, Vacondio F, Silva C, Mor

M, Di Marzo V, Corelli F. Mugnaini C, Brizzi A, Ligresti A, Allarà M, Lamponi

S, Vacondio F, Silva C, Mor M, Di Marzo V, Corelli F. J Med Chem. 2016;

59(3):1052-67.


10. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with

Oxaliplatin and 5-FU in colorectal cancer cells. Fiore D, Proto MC, Pisanti S,

Picardi P, Pagano Zottola AC, Butini S, Gemma S, Casagni A, Laezza C, Vitale

M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Williams DC, Campiani G,

Gazzerro P, Bifulco M. Cancer Biol Ther. 2015 Sep 21:0. [Epub ahead of print].

11. Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An

Integrated Approach. Cerasuolo M, Paris D, Iannotti FA, Melck D, Verde R,

Mazzarella E, Motta A, Ligresti A. Cancer Res. 2015 Aug 1;75(15):2975-86.

12. New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor

agonists with anticancer and immuno-modulatory activity. Manera C, Malfitano

AM, Parkkari T, Lucchesi V, Carpi S, Fogli S, Bertini S, Laezza C, Ligresti A,

Saccomanni G, Savinainen JR, Ciaglia E, Pisanti S, Gazzerro P, Di Marzo V, Nieri

P, Macchia M, Bifulco M. Eur J Med Chem. 2015 Jun 5;97:10-8.

13. Synthesis, biological activity and molecular modeling of new biphenylic

carboxamides as potent and selective CB2 receptor ligands. Bertini S, Parkkari T,

Savinainen JR, Arena C, Saccomanni G, Saguto S, Ligresti A, Allarà M, Bruno A,

Marinelli L, Di Marzo V, Novellino E, Manera C, Macchia M. Eur J Med Chem.

2015 Jan 27;90:526-36. doi: 10.1016/j.ejmech.2014.11.066.

14. Adolescent exposure to THC in female rats disrupts developmental changes in the

prefrontal cortex. Rubino T, Prini P, Piscitelli F, Zamberletti E, Trusel M, Melis

M, Sagheddu C, Ligresti A, Tonini R, Di Marzo V, Parolaro D. Neurobiol Dis.

2015 Jan;73:60-9. doi: 10.1016/j.nbd.2014.09.015.

15. CB2-selective cannabinoid receptor ligands: synthesis, pharmacological

evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-

3-carboxamides. Lucchesi V, Hurst DP, Shore DM, Bertini S, Ehrmann BM,

Allarà M, Lawrence L, Ligresti A, Minutolo F, Saccomanni G, Sharir H, Macchia

M, Di Marzo V, Abood ME, Reggio PH, Manera C. J Med Chem. 2014 Nov

13;57(21):8777-91. doi: 10.1021/jm500807e.

16. Structure-affinity relationships and pharmacological characterization of new alkyl-

resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid

receptor/TRPA1 channel agonist. Brizzi A, Aiello F, Marini P, Cascio MG, Corelli

F, Brizzi V, De Petrocellis L, Ligresti A, Luongo L, Lamponi S, Maione S,

Pertwee RG, Di Marzo V. Bioorg Med Chem. 2014 Sep 1;22(17):4770-83. doi:

10.1016/j.bmc.2014.07.006.

17. Discovery of glycine sulfonamides as dual inhibitors of sn-1-diacylglycerol lipase

α and α/β-hydrolase domain 6. Janssen FJ, Deng H, Baggelaar MP, Allarà M, van

der Wel T, den Dulk H, Ligresti A, van Esbroeck AC, McGuire R, Di Marzo V,

Overkleeft HS, van der Stelt M. J Med Chem. 2014. 57(15):6610-22. doi:

10.1021/jm500681z.

18. 1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for

functionality switch at CB2 cannabinoid receptor. Lucchesi V, Parkkari T,

Savinainen JR, Malfitano AM, Allarà M, Bertini S, Castelli F, Del Carlo S, Laezza

C, Ligresti A, Saccomanni G, Bifulco M, Di Marzo V, Macchia M, Manera C.

Eur J Med Chem. 2014 Mar 3;74:524-32. doi: 10.1016/j.ejmech.2013.10.070.

Epub 2014 Jan 21.

19. Prostamide F(2) α receptor antagonism combined with inhibition of FAAH may

block the pro-inflammatory mediators formed following selective FAAH

inhibition. Ligresti A, Martos J, Wang J, Guida F, Allarà M, Palmieri V, Luongo

L, Woodward D, Di Marzo V. Br J Pharmacol. 2014 Mar;171(6):1408-19. doi:

10.1111/bph.12410.


20. Preparation and characterization of Δ(9)-tetrahydrocannabinol-loaded

biodegradable polymeric microparticles and their antitumoral efficacy on cancer

cell lines. Hernán Pérez de la Ossa D, Gil-Alegre ME, Ligresti A, Aberturas Mdel

R, Molpeceres J, Torres AI, Di Marzo V. J Drug Target. 2013 Sep;21(8):710-8.

doi: 10.3109/1061186X.2013.809089.

21. Biaryl tetrazolyl ureas as inhibitors of endocannabinoid metabolism: modulation at

the N-portion and distal phenyl ring. Ortar G, Morera E, De Petrocellis L, Ligresti

A, Schiano Moriello A, Morera L, Nalli M, Ragno R, Pirolli A, Di Marzo V. Eur J

Med Chem. 2013 May;63:118-32. doi: 10.1016/j.ejmech.2013.02.005.

22. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo:

pro-apoptotic effects and underlying mechanisms. De Petrocellis L, Ligresti A,

Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di

Marzo V. Br J Pharmacol. 2013 Jan;168(1):79-102. doi: 10.1111/j.1476-

5381.2012.02027.x.

23. 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying

agents.Rizzo S, Tarozzi A, Bartolini M, Da Costa G, Bisi A, Gobbi S, Belluti F,

Ligresti A, Allarà M, Monti JP, Andrisano V, Di Marzo V, Hrelia P, Rampa A.

Eur J Med Chem. 2012 Dec;58:519-32.

24. Neural precursor cells induce cell death of high-grade astrocytomas through

stimulation of TRPV1. Stock K, Kumar J, Synowitz M, Petrosino S, Imperatore R,

Smith ES, Wend P, Purfürst B, Nuber UA, Gurok U, Matyash V, Wälzlein JH,

Chirasani SR, Dittmar G, Cravatt BF, Momma S, Lewin GR, Ligresti A, De

Petrocellis L, Cristino L, Di Marzo V, Kettenmann H, Glass R. Nat Med. 2012 Jul

22. doi: 10.1038/nm.2827. [Epub ahead of print].

25. Non-THC cannabinoids counteract prostate carcinoma growth in vitro and in vivo:

pro-apoptotic effects and underlying mechanisms. De Petrocellis L, Ligresti A,

Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di

Marzo V. Br J Pharmacol. 2012 May 18. 168(1):79-102.

26. Poly--caprolactone microspheres as a drug delivery system for cannabinoid

administration: Development, characterization and in vitro evaluation of their

antitumoral efficacy. Hernán Pérez de la Ossa D, Ligresti A, Gil-Alegre ME,

Aberturas MR, Molpeceres J, Di Marzo V, Torres Suárez AI. J Control Release.

2012 Aug 10;161(3):927-32. 6.499

27. Kavalactones and the endocannabinoid system: the plant-derived yangonin is a

novel CB? receptor ligand. Ligresti A, Villano R, Allarà M, Ujváry I, Di Marzo V.

Pharmacol Res. 2012 Aug;66(2):163-9. 4.436

28. Design, synthesis, and pharmacological characterization of indol-3-ylacetamides,

indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2

cannabinoid receptor inverse agonists. Pasquini S, Mugnaini C, Ligresti A, Tafi A,

Brogi S, Falciani C, Pedani V, Pesco N, Guida F, Luongo L, Varani K, Borea PA,

Maione S, Di Marzo V, Corelli F. J Med Chem. 2012 Jun 14;55(11):5391-402.

5.207

29. Indole-2-carboxamides as allosteric modulators of the cannabinoid CB2 receptor.

Piscitelli F, Ligresti A, La Regina G, Coluccia A, Morera L, Allarà M, Novellino

E, Di Marzo V, Silvestri R. J Med Chem. 2012 Jun 14;55(11): 5627-31. 5.207

30. Rational design, synthesis and anti-proliferative properties of new CB2 selective

cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one

scaffold. Manera C, Saccomanni G, Malfitano AM, Bertini S, Castelli F, Laezza

C, Ligresti A, Lucchesi V, Tuccinardi T, Rizzolio F, Bifulco M, Di Marzo V,


Giordano A, Macchia M, Martinelli A. Eur J Med Chem. 2012 Jun;52:284-94.

5.207

31. Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of

the physicochemical profile of a set of potent and selective cannabinoid-2 receptor

ligands through a bioisosteric approach. Mugnaini C, Nocerino S, Pedani V,

Pasquini S, Tafi A, De Chiaro M, Bellucci L, Valoti M, Guida F, Luongo L,

Dragoni S, Ligresti A, Rosenberg A, Bolognini D, Cascio MG, Pertwee RG,

Moaddel R, Maione S, Di Marzo V, Corelli F. ChemMedChem. 2012

May;7(5):920-34. 3.445

32. The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

Rampa, A; Bartolini, M; Bisi, A; Belluti, F; Gobbi, S; Andrisano, V; Ligresti, A;

Di Marzo, V. ACS MEDICINAL CHEMISTRY LETTERS; 2012 3(3) 182-186.

3.355

33. Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics

endowed with high affinity and selectivity for cannabinoid type 1 receptor. Brizzi

A, Cascio MG, Frosini M, Ligresti A, Aiello F, Biotti I, Brizzi V, Pertwee RG,

Corelli F, Di Marzo V. J Med Chem. 2011 Dec 22;54(24):8278-88.

34. Cannabinomimetic lipid from a marine cyanobacterium. Gutiérrez M, Pereira AR,

Debonsi HM, Ligresti A, Di Marzo V, Gerwick WH. J Nat Prod. 2011 Oct

28;74(10):2313-7.

35. 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for

the design of either CB1 or CB2 receptor ligands. Piscitelli F, Ligresti A, La

Regina G, Gatti V, Brizzi A, Pasquini S, Allarà M, Carai MA, Novellino E,

Colombo G, Di Marzo V, Corelli F, Silvestri R. Eur J Med Chem. 2011

Nov;46(11):5641-53.

36. Altered endocannabinoid signalling after a high-fat diet in Apoe (-/-) mice:

relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance.

Bartelt A, Orlando P, Mele C, Ligresti A, Toedter K, Scheja L, Heeren J, Di

Marzo V. Diabetologia. 2011 Nov;54(11):2900-10.

37. Homology modeling in tandem with 3D-QSAR analyses: a computational

approach to depict the agonist binding site of the human CB2 receptor. Cichero E,

Ligresti A, Allarà M, di Marzo V, Lazzati Z, D'Ursi P, Marabotti A, Milanesi L,

Spallarossa A, Ranise A, Fossa P. Eur J Med Chem. 2011 Sep;46(9):4489-505.

38. Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new

potent and selective ligands for the cannabinoid type 2 receptor with diverse

substitution patterns and antihyperalgesic effects in mice. Pasquini S, De Rosa M,

Pedani V, Mugnaini C, Guida F, Luongo L, De Chiaro M, Maione S, Dragoni S,

Frosini M, Ligresti A, Di Marzo V, Corelli F. J Med Chem. 2011 Aug

11;54(15):5444-53.

39. Desulfohaplosamate, a new phosphate-containing steroid from Dasychalina sp., is

a selective cannabinoid CB(2) receptor ligand. Chianese G, Fattorusso E,

Taglialatela-Scafati O, Bavestrello G, Calcinai B, Dien HA, Ligresti A, Di Marzo

V. Steroids. 2011 Apr 19. 76(10-11):998-1002.

40. Anandamide-loaded nanoparticles: preparation and characterization. Aberturas

MR, Hernán Pérez de la Ossa D, Gil ME, Ligresti A, De Petrocellis L, Torres AI,

Di Marzo V, Molpeceres J. J Microencapsul. 2011;28(3):200-10.

41. Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose

tissue, liver and skeletal muscle. Silvestri C, Ligresti A, Di Marzo V. Rev Endocr

Metab Disord. 2011 Feb 19. [Epub ahead of print]


42. Three-dimensional quantitative structure-selectivity relationships analysis guided

rational design of a highly selective ligand for the cannabinoid receptor 2. Brogi S,

Corelli F, Di Marzo V, Ligresti A, Mugnaini C, Pasquini S, Tafi A. Eur J Med

Chem. 2011 Feb;46(2):547-55. Epub 2010 Nov 27.

43. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP

channels and endocannabinoid metabolic enzymes. De Petrocellis L, Ligresti A,

Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Br J

Pharmacol. 2010 Dec 22. [Epub ahead of print]

44. Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-

pyrazole-3-carboxamides as cannabinoid receptor ligands. Silvestri R, Ligresti A,

La Regina G, Piscitelli F, Gatti V, Lavecchia A, Brizzi A, Pasquini S, Allarà M,

Fantini N, Carai MA, Bigogno C, Rozio MG, Sinisi R, Novellino E, Colombo G,

Di Marzo V, Dondio G, Corelli F. Eur J Med Chem. 2010 Dec;45(12):5878-86.

45. Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-

affinity relationships, and pharmacological characterization of 6-substituted 4-

quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.

Pasquini S, Ligresti A, Mugnaini C, Semeraro T, Cicione L, De Rosa M, Guida F,

Luongo L, De Chiaro M, Cascio MG, Bolognini D, Marini P, Pertwee R, Maione

S, Di Marzo V, Corelli F. J Med Chem. 2010 Aug 26;53(16):5915-28.

46. Exploiting nanotechnologies and TRPV1 channels to investigate the putative

anandamide membrane transporter. Ligresti A, De Petrocellis L, Hernán Pérez de

la Ossa D, Aberturas R, Cristino L, Moriello AS, Finizio A, Gil ME, Torres AI,

Molpeceres J, Di Marzo V. PLoS One. 2010 Apr 22;5(4):e10239.

47. Guida M, Ligresti A, De Filippis D, D'Amico A, Petrosino S, Cipriano M, Bifulco

G, Simonetti S, Orlando P, Insabato L, Nappi C, Di Spiezio Sardo A, Di Marzo V,

Iuvone T. The Levels of the Endocannabinoid Receptor CB2 and Its Ligand 2-

Arachidonoylglycerol Are Elevated in Endometrial Carcinoma. Endocrinology.

Endocrinology. 2010 Mar;151(3):921-8.

48. Saturnino C, Petrosino S, Ligresti A, Palladino C, De Martino G, Bisogno T, Di

Marzo V. Synthesis and biological evaluation of new potential inhibitors of N-

acylethanolamine hydrolyzing acid amidase. Bioorg Med Chem Lett. 2010 Feb

1;20(3):1210-3.

49. Morera E, De Petrocellis L, Morera L, Moriello AS, Ligresti A, Nalli M,

Woodward DF, Di Marzo V, Ortar G. Synthesis and biological evaluation of

piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and

transient receptor potential (TRP) channel dual ligands. Bioorg Med Chem Lett.

2009 Dec 1;19(23):6806-9.

50. Pasquini S, Mugnaini C, Brizzi A, Ligresti A, Di Marzo V, Ghiron C, Corelli F.

Rapid combinatorial access to a library of 1,5-disubstituted-3-indole-N-

alkylacetamides as CB2 receptor ligands. J Comb Chem. 2009 Sep-Oct;11(5):795-

8.

51. Silvestri R, Ligresti A, La Regina G, Piscitelli F, Gatti V, Brizzi A, Pasquini S,

Lavecchia A, Allarà M, Fantini N, Carai MA, Novellino E, Colombo G, Di Marzo

V, Corelli F. Synthesis, cannabinoid receptor affinity, molecular modeling studies

and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-

yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the

affinity and selectivity profile. Bioorg Med Chem. 2009 Aug 1;17(15):5549-64.

52. Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, Giordano E,

Sanna F, Bisogno T, Uda S, Collu M, Bruheim I, Di Marzo V, Banni S.

Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat


and inflammatory mediators in obese Zucker rats. J Nutr. 2009 Aug;139(8):1495-

501.

53. Di Marzo V, Ligresti A, Cristino L. The endocannabinoid system as a link

between homoeostatic and hedonic pathways involved in energy balance

regulation. Int J Obes (Lond). 2009 Jun;33 Suppl 2:S18-24.

54. Ligresti A, Petrosino S, Di Marzo V. From endocannabinoid profiling to

'endocannabinoid therapeutics'. Curr Opin Chem Biol. 2009 Jun;13(3):321-31.

55. Petrosino S, Ligresti A, Di Marzo V. Endocannabinoid chemical biology: a tool

for the development of novel therapies. Curr Opin Chem Biol. 2009

Jun;13(3):309-20.

56. Manera C, Saccomanni G, Adinolfi B, Benetti V, Ligresti A, Cascio MG,

Tuccinardi T, Lucchesi V, Martinelli A, Nieri P, Masini E, Di Marzo V, Ferrarini

PL. Rational design, synthesis, and pharmacological properties of new 1,8-

naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-

2 receptor agonists.J Med Chem. 2009 Jun 25;52(12):3644-51.

57. Appendino G, Ligresti A, Minassi A, Cascio MG, Allarà M, Taglialatela-Scafati

O, Pertwee RG, De Petrocellis L, Di Marzo V. Conformationally constrained fatty

acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem.

2009 May 14;52(9):3001-9.

58. Brizzi A, Brizzi V, Cascio MG, Corelli F, Guida F, Ligresti A, Maione S,

Martinelli A, Pasquini S, Tuccinardi T, Di Marzo V. New resorcinol-anandamide

"hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive

activity in vivo. J Med Chem. 2009 Apr 23;52(8):2506-14.

59. Sinning C, Watzer B, Coste O, Nüsing RM, Ott I, Ligresti A, Di Marzo V,

Imming P. (2008) New analgesics synthetically derived from the paracetamol

metabolite N - (4-hydroxyphenyl) - (5Z,8Z,11Z,14Z) – icosatetra - 5,8,11,14 -

enamide. J Med Chem.51(24):7800-5.

60. De Petrocellis L, Deva R, Manieri F, Schaefer M, Bisogno T, Ciccoli R, Ligresti

A, Hill K, Nigam S, Appendino G, Di Marzo V. (2009) Biotransformation of

anandamide by an unicellular fungus and chemical synthesis and pharmacological

characterization and of the resulting 3-hydroxy-derivative. J Lipid Res. 50(4):658-

66.

61. Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V. (2008)

Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-

arachidonoylglycerol metabolism. J Med Chem. 51(21):6970-9.

62. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and

structure-activity relationship of potent and selective cannabinoid-2 receptor

agonists endowed with analgesic activity in vivo. Pasquini S, Botta L, Semeraro T,

Mugnaini C, Ligresti A, Palazzo E, Maione S, Di Marzo V, Corelli F. (2008). J

Med Chem. 51(16):5075-84.

63. Maione S, Morera E, Marabese I, Ligresti A, Luongo L, Ortar G, Di Marzo V.

(2008) Antinociceptive effects of tetrazole inhibitors of endocannabinoid

inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. Br

J Pharmacol. 155(5):775-82.

64. Ortar G, Schiano Moriello A, Cascio MG, De Petrocellis L, Ligresti A, Morera E,

Nalli M, Di Marzo V. (2008) New tetrazole-based selective anandamide uptake

inhibitors. Bioorg Med Chem Lett. 18(9):2820-4.

65. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L,

Laezza C, Portella G, Bifulco M, Di Marzo V. (2006) Antitumor activity of plant


cannabinoids with emphasis on the effect of cannabidiol on human breast

carcinoma. J Pharmacol Exp Ther. 318(3):1375-87.

66. Schiano Moriello A, Balas L, Ligresti A, Cascio MG, Durand T, Morera E, Ortar

G, Di Marzo V. (2006) Development of the first potential covalent inhibitors of

anandamide cellular uptake. J Med Chem. 49(7):2320-32.

67. Di Marzo M, Casapullo A, Bifulco G, Cimino P, Ligresti A, Di Marzo V, Riccio

R, Gomez-Paloma L. (2006) Synthesis, conformational analysis and CB1 binding

affinity of hairpin-like anandamide pseudopeptide mimetics. J Pept Sci. 12(9):575-

91.

68. Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L,

Saha B, Mahadevan A, Visintin C, Wiley JL, Baker D, Martin BR, Razdan RK, Di

Marzo V. (2006) New potent and selective inhibitors of anandamide reuptake with

antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol.

147(1):83-91.

69. Ligresti A, Cascio MG, Di Marzo V. (2005) Endocannabinoid metabolic

pathways and enzymes. Curr Drug Targets CNS Neurol Disord. 4(6):615-23.

Review.

70. Ligresti A., Di Marzo V. (2005). Endocannabinoid-based molecules as potential

therapeutic drugs. Chapter 24 in the Book: Endocannabinoids. The brain and

body’s marijuana beyond. Editori: Emmanuel S. Onaivi, Takayuki Sugiura,

Vincenzo Di Marzo.

71. Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system:

Biochemical aspects. Pharmacol Biochem Behav. 2005 May 31. Review.

72. Appendino G, De Petrocellis L, Trevisani M, Minassi A, Daddario N, Moriello

AS, Gazzieri D, Ligresti A, Campi B, Fontana G, Pinna C, Geppetti P, Di Marzo

V. (2005) Development of the first ultra-potent "capsaicinoid" agonist at transient

receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential.

J Pharmacol Exp Ther. (2):561-70.

73. Di Marzo V., Ligresti A., Morera E., Nalli M., Ortar G. (2004) The anandamide

membrane transporter. Structure-activity relationships of anandamide and

oleoylethanolamine analogs with phenil rings in the polar head group region.

Bioorganic & Medicinal Chemistry. (12): 5161-5169.

74. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G., Di Marzo V. (2004) A

new strategy to block tumor growth by inhibiting endocannabinoid inactivation.

FASEB J., (13):1606-8.

75. Fowler CJ, Tiger G, Ligresti A, Lopez-Rodriguez ML, Di Marzo V. (2004)

Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis-a

difficult issue to handle. Eur. J. Pharmacol., 492(1):1-11.

76. Ligresti A., Morera E., van der Stelt M, Monory K., Lutz B., Ortar G. and Di

Marzo V. (2004) Further evidence for the existence of a specific process for the

membrane transport of anandamide. Biochem. J., 380(Pt 1):265-72.

77. Matias I., Chen J., De Petrocellis L., Bisogno T., Ligresti A., Fezza F., Krauss

A.H., Shi L., Protzman C.E., Li C., Liang Y., Nieves A.L., Kedzie K.M., Burk

R.M., Di Marzo V. and Woodward D.F. (2004) Prostaglandin-ethanolamides

(prostamides): in vitro pharmacology and metabolism. J. Pharmacol. Exp. Ther.,

309(2):745-57.

78. de Lago E., Ligresti A., Ortar G., Morera E., Cabranes A., Pryce G., Bifulco M.,

Baker D., Fernandez-Ruiz J. and Di Marzo V. (2004) In vivo pharmacological

actions of two novel inhibitors of anandamide cellular uptake. Eur. J. Pharmacol.,

484 (2-3): 249-57.


79. Cascio MG., Minassi A., Ligresti A., Appendino G.,Burstein S. and Di Marzo V.

(2004) A structure-activity relationship study on N-arachidonoil-aminoacids as

possible endogenous inhibitors of fatty acid amide hydrolase. Biochem. Biophis.

Res. Commun., 314 (1): 192-6.

80. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., Matias

I., Schiano Moriello A., Paul P., Williams EJ., Gangadharan U., Hobbs C., Di

Marzo V. and Doherty P. (2003) Cloning of the first sn1-DAG lipases points to the

spatial and temporal regulation of endocannabinoid signalling in the brain. J. Cell.

Biol., 163 (3): 463-8.

81. Han B., McPhail KL., Ligresti A., Di Marzo V. and Gerwick WH. (2003)

Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of

the marine cyanobacterium Lyngbya semiplena. J. Nat. Prod., 66(10): 1364-8.

82. Izzo A.A., Capasso F., Costagliela A., Bisogno T., Morsicano G., Ligresti A.,

Matias I., Capasso R., Pinto L., Borrelli F., Cecio A., Lutz B., Mascolo N. and Di

Marzo V. (2003) An endogenous cannabinoid tone attenuates colera toxin-induced

accumulation in mice. Gastroenterology., 125 (3): 765-74.

83. Ligresti A., Bisogno T., Matias I., De Petrocellis L., Laezza C., Cascio M.G:,

Cosenza V., D’Argenio G., Scaglione G., Bifulco M., Sorrentini M., Di Marzo V.

(2003) Possible endocannabinoid control of colorectal cancer growth.

Gastroenterology., 125 (3): 677-87.

84. Ortar G., Ligresti A., De Petrocellis L., Morera E., Di Marzo V. (2003). Novel

selective and metabollically stable inhibitors of anandamide cellular uptake.

Biochem. Pharmacol., 65 (9):1473-81.

85. Appendino G., Ligresti A., Minassi A., Daddario N., Bisogno T., Di Marzo V.

(2003) Homologues and isomers of noladin ether, a putative novel

endocannabinoid: interaction with rat cannabinoid CB1 receptors. Bioorg.

Med.Chem. Lett. 13, 43-46.

86. De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V.( 2002)

Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide

interacting with both the cannabinoid and vanilloid signalling systems.

Fundam Clin Pharmacol., 16(4):297-302.

87. Rossi A., Ligresti A., Longo R., Russo A., Borrelli F., Sautebin L. (2002) The

inhibitory effect of propolis and caffeic acid phenethyl ester on ciclooxygenase

activity in J774 macrophages. Phytomedicine 9,530-535.

88. Mascolo N., Izzo A.A., Ligresti A., Costagliola A., Pinto L., Cascio M.G., Mafia

P., Cecio A., Papasso F., Di Marzo V. (2002) The endocannabinoid system and the

molecular basis of paralytic ileus in mice. FASEB J.16, 1973-1975.

89. Esposito G., Ligresti A., Izzo A.A., Bisogno T., Ruvo M., Di Rosa M., Di Marzo

V., Iuvone T. (2002) The endocannabinoid system protects rat glioma cells against

HIV-1 Tat protein-induced cytotoxicity. Mechannism and regulation. J. Biol.

Chem. 277, 50348-50354.

90. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., Bisogno T. (2002)

Anandamide receptors. Prostaglandine Leukot. Essent. Fatty Acids. Rewiew.

66,377-391.

CHAPTER IN BOOKS

91. Ligresti A., Di Marzo V. (2005). Endocannabinoid-based molecules as potential

therapeutic drugs. Chapter 24 in the Book: Endocannabinoids. The brain and


body’s marijuana beyond. Editori: Emmanuel S. Onaivi, Takayuki Sugiura,

Vincenzo Di Marzo.

92. De Petrocellis L, Nabissi M, Santoni G, Ligresti A. (2017) Actions and regulation

of ionotropic cannabinoid receptors. Chapter 15 in the Book Series Advances in

Pharmacology. (Cannabinoid Pharmacology ,Volume 80). Editori: David Kendall,

Stephen Alexander.

alessia ligresti – curriculum vitae - cnr · alessia ligresti – curriculum vitae january -...

Documents